STUDY PROTOCOL

Study protocol for a process evaluation of a cluster randomised controlled trial to reduce potentially inappropriate prescribing and polypharmacy in patients with multimorbidity in Irish primary care (SPPiRE) [version 1; peer review: 2 approved with reservations]

Karen Kyne¹, Caroline McCarthy¹, Bridget Kiely¹, Susan M. Smith¹, Barbara Clyne¹, SPPiRE Study team

¹Department of General Practice, Royal College of Surgeons in Ireland, Dublin, Ireland

Abstract
Background: Multimorbidity (the presence of two or more chronic conditions) is associated with poorer health outcomes, particularly for patients with significant polypharmacy (≥15 medications), due to the higher risk of adverse events and drug interactions. The SPPiRE study will assess the effectiveness of a complex intervention to support general practitioners (GPs) to reduce potentially inappropriate prescribing and consider deprescribing in older people with multimorbidity and significant polypharmacy. The aim of the SPPiRE process evaluation is to understand how and why the intervention is effective or ineffective and to explore the potential for system wide implementation of the intervention using the Medical Research Council general themes of context, implementation and mechanism of impact.

Methods: The SPPiRE study is a clustered randomised controlled trial (RCT), aiming to recruit 55 general practices and 400 patients (≥65 years) on ≥15 medications throughout the Republic of Ireland. This mixed-methods process evaluation of the SPPiRE study will integrate both quantitative and qualitative data. Quantitative data will be collected on use of the intervention elements and from GP questionnaires. Qualitative data will be collected from semi-structured telephone interviews with all intervention GPs and a purposeful sample of patients from intervention practices. The topic guide will explore barriers and facilitators to participation and implementation of the intervention. Quantitative data will be analysed using descriptive statistics. Interviews will be transcribed and analysed using thematic analysis. Quantitative and qualitative data will be then be integrated.

Discussion: The SPPiRE cluster RCT will provide evidence regarding...
the effectiveness and practicability of delivering a structured medication review in reducing polypharmacy and potentially inappropriate prescribing for patients with multimorbidity. This process evaluation will provide information on how the intervention was implemented, how it was or was not effective and the potential for a system wide implementation.

**Trial registration:** ISRCTN 12752680, registration: 20/10/2016

**Keywords**
Multimorbidity, Polypharmacy, Deprescribing, Randomised Controlled Trial, Process evaluation

This article is included in the Ageing Populations collection.
Background

Complex interventions involve a number of interacting components and often offer a degree of flexibility, or tailoring to the local environment\(^1\). Therefore, it is often difficult to ascertain why a complex intervention was or was not effective, and if effective, what components of the intervention were responsible for that effect. The Medical Research Council (MRC) advise performing a process evaluation alongside the effectiveness evaluation of a complex intervention to assess how it was implemented, how it caused change and how the intervention interacted with the context in which it was implemented\(^2\). This provides important information for policy makers on how a complex intervention might be implemented more widely into the healthcare system. A framework to guide process evaluations designed for cluster randomised controlled trials\(^3\) advises that process evaluations should clearly state their purpose and research questions and as recommended by the MRC guideline, this paper sets out to pre-specify our process evaluation research questions and methods.

Supporting prescribing in multimorbidity in primary care (SPPiRE)

There is a growing consensus that the current single disease framework is not appropriate when managing patients with multiple chronic conditions or multimorbidity, and that adhering to multiple single disease guidelines may lead to significant polypharmacy and inappropriate treatment burden for patients\(^4\). The National Institute for Clinical Excellence (NICE) multimorbidity guideline advises tailoring care to the individual and that due to the link between complex multimorbidity and polypharmacy, patients who are prescribed \(\geq 15\) repeat medicines should be specifically targeted and offered an individualised structured medication review\(^5\). SPPiRE is a cluster randomised controlled trial (RCT) that is assessing the effectiveness of an intervention designed to support general practitioners (GPs) in reducing significant polypharmacy and potentially inappropriate prescribing (PIP) in older patients aged \(\geq 65\) years with multimorbidity in Irish primary care\(^6\). Details of the trial design have been described elsewhere\(^7\).

Briefly, the SPPiRE has been developed from previous research and current literature (see Figure 1). Our study group had previously found a complex intervention comprising academic detailing and a GP-led medicines review was effective in reducing potentially inappropriate prescribing (OPTI-SCRIPT trial)\(^8\). The SPPiRE intervention evolved based on the OPTI-SCRIPT process evaluation\(^9\) and emerging evidence in the area of deprescribing and high risk prescribing\(^9,10\).

The SPPiRE intervention will be delivered at the cluster level to intervention GPs in the form of access to the SPPiRE website. The website has links to training videos and provides structure for the medication review, where the GP will be prompted to check for specific PIP that have been pre-selected using the updated Screening tool of older persons prescriptions (STOPP 2)\(^11\), based on their association with preventable drug related morbidity\(^12\) and their prevalence in Irish primary care\(^13\), as well as recently developed and validated monitoring criteria\(^14\). GPs will also be prompted to assess their patients’ priorities about treatment and ask them if they have concerns about their medications. The components of the SPPiRE intervention are described in Table 1.

![Figure 1. Development and evaluation of the SPPiRE intervention adapted from the MRC framework\(^1\).](image-url)

<table>
<thead>
<tr>
<th>Table 1. SPPiRE intervention components.</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPPiRE intervention component</td>
</tr>
<tr>
<td>---------------------------------</td>
</tr>
</tbody>
</table>
| Training videos | - demonstrate how to perform a SPPiRE medication review  
- describe key concepts - polypharmacy, PIP, multimorbidity and treatment burden |
| Medication review | Online medication review template which provides a structured process. GPs guided to:  
1. Screen patient prescriptions for PIP and high risk prescribing  
2. Assess the patient’s treatment priorities  
3. Review each medicine with the patient  
4. Agree all changes with the patient |
The MRC guideline on process evaluations for complex interventions advises that the various components of the intervention should be clearly described as should the mechanisms through which these components are expected to produce change. These causal assumptions may be based on theory but in the case of complex interventions are often based on common sense and past experience, as is the case with the SPPiRE intervention. Similarly recommendations from a framework for process evaluations for cluster RCTs advises pre-specifying the hypothesized pathway of change through which the intervention is anticipated to exert its effect. Figure 2 illustrates the hypothesized pathway of change for the SPPiRE medication review.

In line with the NICE multimorbidity Guidance, GPs are also prompted to assess the patient’s treatment priorities. There is very little in the published literature on how to best to assess patient treatment priorities. A systematic review identified only one patient priority assessment tool that has been used and validated in people with multimorbidity. The effectiveness and mechanism effect of this novel aspect of the SPPiRE intervention will be explored in the process evaluation using both qualitative and quantitative methods.

The purpose of the brown bag medication review is to incorporate the patient’s ideas and concerns about their medicines and to identify and deprescribe medicines that may not constitute high risk PIP but are inappropriate none the less as they are ineffective or have risks that outweigh benefits in the particular individual. Qualitative work with doctors has highlighted several barriers to deprescribing, including feasibility issues, prescriber confidence and prioritization (or lack of) of deprescribing. However qualitative work with patients indicates that most would be agreeable to deprescribing medication if supported by their GP. These more nuanced areas of doctor and patient attitudes to deprescribing will be explored qualitatively in the process evaluation.

Aims and objectives of the SPPiRE process evaluation

The overall aim of the SPPiRE process evaluation is to explore how and why the intervention was effective or ineffective and the potential for system wide implementation of the SPPiRE intervention in Irish primary care. Using the MRC framework, the general themes of context, implementation and mechanism of impact will be explored. Elements for reporting of process evaluations of cluster RCTs were also incorporated, as were recommendations that advise providing a detailed examination of the process of recruitment (see Figure 3).

We will address four main themes; recruitment, implementation, mechanism of impact and the effect of the context. The specific objectives within each theme are described below.

1. Recruitment
   - To explore the barriers and facilitators of cluster and participant recruitment

2. Context
   - Does effectiveness vary between practices? If so how are practice characteristics (e.g. single handed versus group practice) associated with patient recruitment, fidelity of implementation and effectiveness of the intervention?
3. Implementation
   - To explore how the intervention was implemented, including the fidelity of implementation and the barriers and facilitators of implementation.

4. Mechanism of action of the intervention
   - Does the intervention result in change as assumed? What were the effective and ineffective components of the intervention?
   - How do GPs and patients respond to the intervention? Do they view it positively? Are there any unexpected negative or positive consequences of the intervention?

Methods
This is a mixed-methods process evaluation which will integrate both qualitative and quantitative data to address the predetermined research objectives outlined above. Quantitative data will be analysed using Stata V13 and the qualitative data will be analysed using NVivo 12.

The SPPiRE process evaluation will run parallel to the main trial where both trial and process evaluation data collection will be contemporaneous. More detailed methods for each research theme are described below.

Methods for research theme 1: Recruitment

Study design. The overall aim of exploring recruitment is to assess the generalizability of results of the SPPiRE trial. Quantitative data pertaining to recruitment will be reported as part of the trial results according to CONSORT requirements19.

We will also explore why recruited practices agreed to take part and describe the barriers and facilitators of patient recruitment by individual clusters using both qualitative and quantitative methods.

Study population. The study population will comprise of all recruited GP practices and patients.

Data collection. Quantitative data on practice size, location and organisation will be obtained from a practice profile questionnaire (Extended data) and the patient recruitment uptake will be analysed according to these factors. We hypothesize that smaller/single handed practices will have higher uptake rates.

Semi structured interviews (Extended data) will be conducted via telephone with at least one GP from each recruited practice. Telephone interviewing is generally used where time or costs are issues, and evidence suggests there is little difference in the answers obtained this way20.

Plan of analysis. Differences between intervention practices will be described using summary statistics. The interviews will be audio-recorded (with the informed consent of the participating GPs and patients) and transcribed verbatim. Thematic analysis will be conducted by one investigator, and cross-checked by members of the research team to increase rigour and the validity of the findings21.

Methods for research theme 2: Context

Study design. This theme will be explored using mixed quantitative and qualitative methods. It is hypothesised that effects will vary according to practice characteristics. The
effects in smaller practices may be more concentrated compared to larger practices where some GPs may be more interested in the intervention than others. It is hypothesised that practices that already have a rigorous system in place for managing repeat prescriptions and long-term medications may adopt the intervention more readily. It is also hypothesised that GPs working in rural areas will be more likely to intervene and change any identified problem medicines as their patients may have less ready access to hospital specialists. These hypotheses will be tested using quantitative and qualitative data.

**Study population.** The study population will comprise of all recruited GP practices.

**Data collection.** Practice characteristics including size (number of GP sessions per week) and location (urban, rural or mixed) will be collected on the practice profile questionnaire. Thematic analysis and interpretation will be performed by one investigator and cross-checked by members of the research team to increase the validity of the findings. Website usage data will be analysed using descriptive statistics.

**Methods for research theme 4: Mechanism of impact**

**Study design.** This research theme will be explored using both quantitative and qualitative methods. Quantitative data will be derived from the SPPiRE website. The final process of the SPPiRE medication review involves inputting the action taken or change made for each identified PIP and each medicine highlighted by the patient as causing concern. Qualitative methods will include performing semi-structured interviews with both intervention GPs and patients. The intervention components and the proposed causal assumptions for change will form the basis of the topic guide for these interviews. Open and probing questions will also encourage participants to describe any unintended consequences of the intervention and their response to the intervention.

**Study population.** The study population will comprise all intervention GPs and a purposive sample of intervention patients, to include older and younger groups, male and female patients and those on 15 medicines as well as those on over 20 medicines. A sample of 15–20 patients is proposed.

**Data collection.** Clinical and prescribing decisions made during the medication review (e.g. stop or start medicine, refer for monitoring blood test) will be retrieved from the SPPiRE website database. Upon completion of the web guided medication review intervention, GPs will be instructed to print an immediate post intervention prescription. This will also be used to assess the most effective components of the intervention.

Qualitative data will be collected from patients and GPs using semi-structured interviews (*Extended data*). Patient interviews will be conducted either in person or via telephone.

**Data analysis.** Website data and post intervention prescriptions will be analysed to assess which PIP were acted upon and which aspects of the intervention were most effective. The results will be described using descriptive statistics.

Interview transcripts will be analysed using thematic analysis. The response to and impact of the various intervention components will be analysed.

**Final analysis**

The final stage of analysis will be to draw together the findings from the quantitative analysis and qualitative analysis across the four research themes to create an understanding of why the intervention did (or did not) work in all or some contexts and identify implications for longer term implementation if appropriate.

**Dissemination of results**

The results of the Trial will be presented at national and international conferences including The Association of University
Department of General Practice in Ireland (AUDGPI) and Society for Academic Primary Care (SAPC) and we plan to publish the results in peer reviewed journals.

Discussion
At the time of finalising this protocol, patient and practice recruitment to the SPPiRE trial has commenced with ongoing patient recruitment and intervention implementation.

Running the process evaluation parallel to the main trial has the advantage of reducing recall bias of participants and interview bias where researchers, aware of the results of trial outcome data, may influence participants with their preconceived ideas about the reasons for the outcomes. The main disadvantage of this approach is that it is not possible to focus on practices showing extreme positive or negative effects. We have addressed this by choosing to interview at least one GP from all recruited practices.

It is in this context that the SPPiRE intervention is being evaluated, the effect of this on both recruitment and implementation of the intervention will be explored.

If the SPPiRE intervention is effective in reducing PIP and polypharmacy in older patients, this process evaluation will delineate what components of the intervention were most effective and provide some insight into the generalisability of the findings to Irish general practice. Similarly, if the intervention is ineffective the process evaluation will shed light on whether the hypothesized pathway of change was flawed or whether the overall context interfered with implementation of the intervention.

Ethics approval and consent to participate
Full ethical approval for the study was granted by the Irish College of General Practitioners Research Ethics Committee (ICGP REC, SPPiRE Study). Written informed consent will be sought from all patients and GP’s participating in the study.

Data availability
Underlying data
No data is associated with this article.

Extended data

This project contains the following extended data:
- Practice profile questionnaire
- Interview topic guide GPs
- Interview topic guide patients
- Follow-up data collection form
- Adverse drug withdrawal report form

Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).

Grant information
Health Research Board Ireland [Primary Care Clinical Trials Network; CTN-2014-011].

The funding body had no role in the design of the study or in writing the manuscript.

Acknowledgments
We wish in particular to acknowledge the contribution made at all stages of this research by the SPPiRE study team.

References

Open Peer Review

Current Peer Review Status:  

Version 1

Reviewer Report 26 September 2019

https://doi.org/10.21956/hrbopenres.13998.r26777

© 2019 Mann C. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cindy Mann

Centre for Academic Primary Care, National Institute for Health Research School for Primary Care Research, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK

This seems overall a well-planned process evaluation of the SSPiRE cluster randomised trial, organised into four main themes of interest to the process evaluation and reporting the methods, data collection and planned analysis of each. It was mainly clearly described except that there were places where I found it a little difficult to understand because of a lack of detail. In particular it would be easier to understand the quantitative aspects of the process evaluation if the intervention were described more fully. I have looked up the published protocol referenced in the paper, which was helpful, but suggest that even so a little more detail in this paper would enhance the clarity.

On page 4 you refer to a patient priority assessment tool and then say; 'The effectiveness and mechanism effect of this novel aspect of the SPPiRE intervention will be explored in the process evaluation'. Does this mean that you will be using the referenced tool? If so, it would help if this was more explicit. Again, more detail about the content of the intervention would help here.

Are there any hypothesised mechanisms of action that you are specifically evaluating? Figure 2 is more of a flow chart than an illustration of causal assumptions for change and it would be very interesting to have an additional diagram that illustrated hypothesised mechanisms of action. This would potentially give a stronger rationale to underpin the design of the process evaluation.

On page 6 you state that ‘quantitative data will be obtained from the SSPiRE website’ and then that ‘website usage data will be analysed using descriptive statistics’. Could you explain this a bit more? Will GPs performing medication reviews be required to enter data in a template for the reviews that reflect each step in the structured process? Is the intention that researchers will then be able to tell which steps have been completed and thus evaluate the effectiveness of each component?

You state that 55 practices will be involved but only 400 patients, presumably meaning there will be only 7-8 patients per practice. You hypothesize that ‘smaller/single handed practices will have
higher uptake rates'. Does this mean uptake by the GPs or by the invited patients or both? If there are only a small number of patients taking part in the intervention per practice, it will be challenging to detect differences between practices in scale of implementation and effectiveness, but I may have misunderstood what you mean by ‘effects in smaller practices may be more concentrated compared to larger practices where some GPs may be more interested in others’ on page 6. It would be helpful if you could clarify what is meant here.

Also on page 6, could you clarify how the post-intervention prescription will be ‘used to assess the most effective components of the intervention’?

Finally, I noticed a couple of typos on page 6: ‘collection action’ needs changing to ‘collective action’ and ‘reflex’ needs changing to ‘reflexive’

Is the rationale for, and objectives of, the study clearly described?
Yes

Is the study design appropriate for the research question?
Yes

Are sufficient details of the methods provided to allow replication by others?
Partly

Are the datasets clearly presented in a useable and accessible format?
Not applicable

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Process evaluation researcher in complex healthcare trials related to multimorbidity

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 17 Jan 2020
Karen Kyne, Royal College of Surgeons in Ireland, Dublin, Ireland

Response to Reviewer 1 comments - Dr Cindy Mann

- This seems overall a well-planned process evaluation of the SPiRE cluster randomised trial, organised into four main themes of interest to the process evaluation and reporting the methods, data collection and planned analysis of each. It was mainly clearly described except that there were places where I found it a little difficult to understand because of a lack of detail. In particular it would be easier to understand the quantitative aspects of the process evaluation if the intervention were described more fully. I have looked up the published protocol referenced in the paper, which was helpful, but suggest that even so a little more detail in this paper...
would enhance the clarity.

**Author's response:**
We have provided more detail. The text added is highlighted in red.
- On page 4 you refer to a patient priority assessment tool and then say; ‘The effectiveness and mechanism effect of this novel aspect of the SPPiRE intervention will be explored in the process evaluation’. Does this mean that you will be using the referenced tool? If so, it would help if this was more explicit.

**Author response**
We have clarified this by the addition of the following text on page 6:
“A systematic review identified only one patient priority assessment tool that has been used and validated in people with multimorbidity. 15, 16 This tool was not included as part of the SPPiRE intervention. The effectiveness and mechanism effect of this novel aspect of the SPPiRE intervention will be explored in the process evaluation using both qualitative and quantitative methods.”
- Are there any hypothesised mechanisms of action that you are specifically evaluating?

**Author response:**
We have clarified this on page 6 with the addition of text in red that no specific mechanisms of action have been prespecified for evaluation.
- Figure 2 is more of a flow chart than an illustration of causal assumptions for change and it would be very interesting to have an additional diagram that illustrated hypothesised mechanisms of action. This would potentially give a stronger rationale to underpin the design of the process evaluation.

**Author response:**
We haven't prespecified mechanisms of action. We are examining the process and trying to establish the mechanisms of action as described in the red text added on page 6. We do not think it would be helpful to add another diagram.
- On page 6 you state that ‘quantitative data will be obtained from the SSSPIRE website’ and then that 'website usage data will be analysed using descriptive statistics'. Could you explain this a bit more?

**Author response**
We have clarified this by the addition of the following text in red on page 9.
“Quantitative data will be obtained from the SPPiRE website. This will include data on GP activity (how often the website was used), the types of PIP and actions taken, and data on patient priorities. Website usage data will be analysed using descriptive statistics (means, frequencies etc.) to summarise the use of the website and the types of PIP and actions taken.”
- Will GPs performing medication reviews be required to enter data in a template for the reviews that reflect each step in the structured process? Is the intention that researchers will then be able to tell which steps have been completed and thus evaluate the effectiveness of each component?

**Author response**
Yes, GP's will be required to enter the data on the template provided which will enable researchers to tell which steps have been completed and thus evaluate the effectiveness of each component. The following text has been added on page 10 which is highlighted in red.
‘This data will be entered by the GP's during the medication review process.’
You state that 55 practices will be involved but only 400 patients, presumably meaning there will be only 7-8 patients per practice. You hypothesize that ‘smaller/single handed practices will have higher uptake rates’. Does this mean uptake by the GPs or by the invited patients or both?

Author's response
This refers to patient uptake. Our experience is that smaller practices are more likely to recruit patients, likely due to better continuity of care between individual GPs and patients.

If there are only a small number of patients taking part in the intervention per practice, it will be challenging to detect differences between practices in scale of implementation and effectiveness, but I may have misunderstood what you mean by ‘effects in smaller practices may be more concentrated compared to larger practices where some GPs may be more interested in others’ on page 6. It would be helpful if you could clarify what is meant here.

Author's response
The rationale for this is that single handed GP’s are often located in rural more remote locations, tend to be further away from hospitals and have less access to specialist services. Hence would be more likely to participate in these projects.

We agree with the statement above.

We have added the following text in red to the article ‘Although this may be hard to distinguish given the number of patients per practice.’ On page 8.

Also on page 6, could you clarify how the post-intervention prescription will be ‘used to assess the most effective components of the intervention’?

Author's response
We have clarified this with the addition of text in red on page 9 and 10.

Finally, I noticed a couple of typos on page 6: ‘collection action’ needs changing to ‘collective action’ and ‘reflex’ needs changing to ‘reflexive’

Author's response
We have changed it to collective action and reflexive on page 9.

Competing Interests: N/A
This protocol could benefit from a brief description of the trial design. Is this a two arm trial? It appears there is only data collection in the intervention arm? This could result in the hawthorne effect and the process evaluation could be responsible for some of the effect observed within in the trial. If my assumption is correct then as well as a brief description of the trial this should be acknowledged in the limitations.

An understanding of the primary outcome would be useful too.

The introduction would also benefit from a brief description of the organisation of the Irish health care system. There is an assumption the reader knows but as a Scot I do not. This is important to interpret context.

Furthermore the mechanisms of action definition seems to be an over simplification. There is not reflection of the relationship of the intervention components and the fact the whole can be greater than the sum of the effects.

**Is the rationale for, and objectives of, the study clearly described?**
Yes

**Is the study design appropriate for the research question?**
Yes

**Are sufficient details of the methods provided to allow replication by others?**
Yes

**Are the datasets clearly presented in a useable and accessible format?**
Not applicable

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Process evaluation methodology, Sociology of prescribing

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

**Author Response 17 Jan 2020**

**Karen Kyne**, Royal College of Surgeons in Ireland, Dublin, Ireland

**Response to Reviewer 2 comments: Dr Aileen Grant**

- This a well designed process evaluation however I feel there is some crucial information missing which would aid the reader in interpretation. This protocol could benefit from a brief description of the trial design. Is this a two arm trial? It appears there is only data collection in the intervention arm? This could result in the hawthorne effect and the process evaluation could be responsible for some of the effect observed within in the trial. If my assumption is correct then as well as a brief
description of the trial this should be acknowledged in the limitations.

Author's response:
More information on the trial, has been added to the text in red font on page 3.
As per previous comments above, we have given more information on the intervention.
  ○ An understanding of the primary outcome would be useful too.

Author's response:
More information on this has been added to the article in red font on page 3.
  ○ The introduction would also benefit from a brief description of the organisation of the Irish health care system. There is an assumption the reader knows but as a Scot I do not. This is important to interpret context.

Author's response:
A brief explanation of the Irish Healthcare system has been added to the text in red font on page 3.
  ○ Furthermore, the mechanisms of action definition seems to be an over simplification. There is not reflection of the relationship of the intervention components and the fact the whole can be greater than the sum of the effects.

Author's response:
We have updated this based on reviewer 1 comments as outlined by the text in red in the article.

Competing Interests: n/a